IL296247A - Novel compounds for use in the treatment and/or prevention of an angiotensin ii-related disease, disorder or condition - Google Patents

Novel compounds for use in the treatment and/or prevention of an angiotensin ii-related disease, disorder or condition

Info

Publication number
IL296247A
IL296247A IL296247A IL29624722A IL296247A IL 296247 A IL296247 A IL 296247A IL 296247 A IL296247 A IL 296247A IL 29624722 A IL29624722 A IL 29624722A IL 296247 A IL296247 A IL 296247A
Authority
IL
Israel
Prior art keywords
methyl
butyl
sulfonyl
imidazol
carbamate
Prior art date
Application number
IL296247A
Other languages
English (en)
Hebrew (he)
Original Assignee
Vicore Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma Ab filed Critical Vicore Pharma Ab
Publication of IL296247A publication Critical patent/IL296247A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL296247A 2020-03-19 2021-03-18 Novel compounds for use in the treatment and/or prevention of an angiotensin ii-related disease, disorder or condition IL296247A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE2050301 2020-03-19
SE2050782 2020-06-29
PCT/GB2021/050680 WO2021186185A1 (en) 2020-03-19 2021-03-18 Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin ii

Publications (1)

Publication Number Publication Date
IL296247A true IL296247A (en) 2022-11-01

Family

ID=75339995

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296247A IL296247A (en) 2020-03-19 2021-03-18 Novel compounds for use in the treatment and/or prevention of an angiotensin ii-related disease, disorder or condition

Country Status (14)

Country Link
US (1) US20230159467A1 (enExample)
EP (1) EP4121165A1 (enExample)
JP (1) JP7901534B2 (enExample)
KR (1) KR20230004501A (enExample)
CN (1) CN115605265B (enExample)
AU (1) AU2021238939A1 (enExample)
BR (1) BR112022018549A2 (enExample)
CA (1) CA3175559A1 (enExample)
CL (1) CL2022002540A1 (enExample)
CO (1) CO2022014673A2 (enExample)
IL (1) IL296247A (enExample)
MX (1) MX2022011613A (enExample)
PH (1) PH12022552413A1 (enExample)
WO (1) WO2021186185A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202113583D0 (en) * 2021-09-23 2021-11-10 Vicore Pharma Ab New compounds
JP2024511453A (ja) * 2021-03-23 2024-03-13 ヴィコール ファルマ アーベー 選択的アンジオテンシンii受容体リガンド
GB202104033D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
CA3222721A1 (en) * 2021-07-09 2023-01-12 Nadia Nasser PETERSEN New selective angiotensin ii compounds
JP2024178482A (ja) * 2021-11-15 2024-12-25 株式会社アークメディスン 化合物、アンジオテンシンiiタイプ1受容体拮抗剤及び医薬組成物
WO2024133942A1 (en) 2022-12-22 2024-06-27 Vicore Pharma Ab A method of treating a patient diagnosed with an interstitial lung disease
CN120569378A (zh) * 2023-01-09 2025-08-29 维科尔药物公司 选择性血管紧张素ii化合物
CN119504723A (zh) * 2023-08-25 2025-02-25 武汉人福创新药物研发中心有限公司 作为at2r激动剂的噻吩磺酰基氨基甲酸酯
WO2025146172A1 (zh) * 2024-01-03 2025-07-10 武汉人福创新药物研发中心有限公司 一种并环类化合物作为at2r激动剂
WO2025252142A1 (zh) * 2024-06-07 2025-12-11 江苏柯菲平医药股份有限公司 一种血管紧张素ii型2受体激动剂及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198438A (en) * 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
JP4707321B2 (ja) * 2001-05-31 2011-06-22 ヴィコール・ファルマ・アーベー アンギオテンシンiiアゴニストとして有用な三環式化合物
AU2003302106A1 (en) 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
AU2006235698B2 (en) * 2005-04-12 2012-03-29 Vicore Pharma Ab New tricyclic angiotensin II agonists
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
DE102012004589A1 (de) 2012-03-09 2013-09-12 Forschungszentrum Jülich GmbH Agonisten des Angiotensin II AT2-Rezeptors zur Behandlung neurodegenerativer Erkrankungen
US20170266164A1 (en) 2014-12-12 2017-09-21 Vicore Pharma Ab New methods and uses
WO2016107879A2 (en) 2014-12-30 2016-07-07 Vicore Pharma Ab New use of angiotensin ii receptor agonists
HK1244232A1 (zh) 2015-03-02 2018-08-03 维科尔药物公司 用於治疗肺纤维化的血管紧张素ii受体激动剂
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy

Also Published As

Publication number Publication date
AU2021238939A1 (en) 2022-11-10
CO2022014673A2 (es) 2023-01-16
MX2022011613A (es) 2022-10-21
JP7901534B2 (ja) 2026-08-06
CN115605265A (zh) 2023-01-13
CN115605265B (zh) 2026-01-23
EP4121165A1 (en) 2023-01-25
WO2021186185A1 (en) 2021-09-23
KR20230004501A (ko) 2023-01-06
BR112022018549A2 (pt) 2022-11-29
CA3175559A1 (en) 2021-09-23
PH12022552413A1 (en) 2024-01-08
CL2022002540A1 (es) 2023-04-21
US20230159467A1 (en) 2023-05-25
JP2023518948A (ja) 2023-05-09

Similar Documents

Publication Publication Date Title
US20230159467A1 (en) Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin ii
JP7771049B2 (ja) 新化合物
CA3075892C (en) Heterocyclic compounds for the treatment and/or prevention of inflammatory diseases
AU2013365742A1 (en) Autotaxin inhibitors
CA3189240A1 (en) Novel compounds for use in the treatment of diseases associated with angiotensin ii
US12441718B2 (en) Selective angiotensin II compounds
GB2605148A (en) New compounds
JP2024511452A (ja) 選択的アンジオテンシンii受容体リガンド
WO2024149712A1 (en) Selective angiotensin ii compounds
EP4313953A1 (en) Selective angiotensin ii receptor ligands
WO2022200787A1 (en) Selective angiotensin ii receptor ligands
EA049950B1 (ru) Новые соединения, используемые для лечения и/или профилактики заболевания, расстройства или состояния, связанного с ангиотензином ii
HK40081690A (en) Imidazolyl thiophene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii